Details of Disease

General Information of Disease (ID: DISVGXN0)

• Disease Name: Eating disorder
• Synonyms: eating disorder; feeding and eating disorder
• Disease Class: 6B82: Binge eating disorder
• Definition: A broad group of psychological disorders with abnormal eating behaviors leading to physiological effects from overeating or insufficient food intake.
• Disease Hierarchy:
  DISKFW6V: Psychiatric disorder
  DIS0W6QK: Nutritional disorder
  DISVGXN0: Eating disorder
• ICD Code:
  ICD-11: ICD-11: 6B82
  ICD-10: ICD-10: F50, F98.2
  Expand ICD-11: '6B8Z
  Expand ICD-10: 'F50; 'F50.4; 'F50.5; 'F50.8; 'F50.9; 'F98.2
  Expand ICD-9: 278,307.5,401,428.0
• Disease Identifiers:
  MONDO ID: MONDO_0005451
  MESH ID: D001068
  UMLS CUI: C0013473
  MedGen ID: 4434
  SNOMED CT ID: 72366004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Dasotraline	DMLDQFV	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
OPNT001	DMYG1ZQ	Phase 2	NA	[1]
EP-51216	DM49RI7	Phase 1	Small molecular drug	[2]
EP-51389	DMW739O	Phase 1	NA	[2]
NBI-34041	DM5BQK3	Phase 1	Small molecular drug	[2]

This Disease is Treated as An Indication in 6 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Axovan-3	DM1JN6A	Discontinued in Phase 1	NA	[2]
RWJ-49815	DMUGZMO	Terminated	Small molecular drug	[2]
SR 120819A	DMETDFM	Terminated	Small molecular drug	[4]
SR-27950	DMZ8SXP	Terminated	NA	[5]
UCL-1390	DMD3CA5	Terminated	Small molecular drug	[6]
WAY-100635	DMG58FX	Terminated	Small molecular drug	[7]

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AR-R-1589	DMMD8VY	Preclinical	NA	[3]
FR-79620	DMXR287	Preclinical	Small molecular drug	[3]

This Disease is Treated as An Indication in 4 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
KI-1003	DMKKG2V	Investigative	NA	[8]
NPY-1 antagonist	DM1MOG8	Investigative	Small molecular drug	[9]
S-19528	DM589XM	Investigative	NA	[2]
S-25585	DMBUD1M	Investigative	Small molecular drug	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 20 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
GHSR	TTWDC17	Limited	Biomarker	[10]
HDAC4	TTTQGH8	Limited	Posttranslational Modification	[11]
HTR2C	TTWJBZ5	Limited	Genetic Variation	[12]
OXTR	TTSCIUP	Limited	Genetic Variation	[13]
ABCG1	TTMWDGU	moderate	Genetic Variation	[14]
CCKAR	TTCG0AL	moderate	Genetic Variation	[15]
CNTFR	TTT2F9E	moderate	Biomarker	[16]
DYRK3	TTV4EX0	moderate	Biomarker	[17]
NPY5R	TTY6EWA	moderate	Biomarker	[18]
RXFP3	TT64ZVP	moderate	Biomarker	[19]
CRHR1	TT7EFHR	Strong	Biomarker	[20]
DRD4	TTE0A2F	Strong	Genetic Variation	[21]
GHRL	TT1OCL0	Strong	Genetic Variation	[22]
GRIK3	TTNP6O2	Strong	Biomarker	[13]
HTR1D	TT6MSOK	Strong	Genetic Variation	[23]
MBOAT4	TTSYOWR	Strong	Biomarker	[24]
MCL1	TTL53M6	Strong	Genetic Variation	[25]
OPRD1	TT27RFC	Strong	Genetic Variation	[26]
TPH2	TT3KLDP	Strong	Genetic Variation	[27]
UTS2	TTERU0T	Strong	Biomarker	[28]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
SCLY	DEH4TD6	Strong	Biomarker	[29]

This Disease Is Related to 21 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
EBPL	OT59J1GY	Limited	Biomarker	[30]
CARTPT	OTTE4V9S	moderate	Genetic Variation	[31]
DBT	OT4KZ5R9	moderate	Biomarker	[32]
ELOC	OT0XHHWP	moderate	Biomarker	[33]
GABBR1	OTU5A52J	moderate	Biomarker	[34]
IK	OTWSSXX0	moderate	Biomarker	[17]
MOS	OTNMQPFJ	moderate	Genetic Variation	[35]
NEGR1	OT57ECW9	moderate	Biomarker	[36]
PCSK1N	OT7ZRW2F	moderate	Biomarker	[37]
RLN3	OTQSQMUQ	moderate	Biomarker	[19]
ATP8A2	OTDZC2ZT	Strong	Genetic Variation	[38]
DLX4	OTLWVCN4	Strong	Biomarker	[39]
FLNB	OTPCOYL6	Strong	Genetic Variation	[38]
FXR1	OTEMQ1SR	Strong	Genetic Variation	[14]
GPCPD1	OTFE3RCV	Strong	Biomarker	[40]
KRT7	OTLT3JFN	Strong	Biomarker	[29]
NNAT	OTNRLO7G	Strong	Genetic Variation	[41]
RASGRF2	OT67DAGF	Strong	Genetic Variation	[38]
SMIM20	OTZI1KFR	Strong	Altered Expression	[42]
SPX	OTY3G4AR	Strong	Biomarker	[42]
TAL1	OTX4K6QZ	Strong	Biomarker	[29]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
• [3] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1530).
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001260)
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005172)
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 80).
• [8] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [9] Neuropeptide Y receptor antagonists. IDrugs. 2001 Aug;4(8):920-7.
• [10] Genetics of the ghrelin system.Endocr Dev. 2013;25:25-40. doi: 10.1159/000348665. Epub 2013 Apr 25.
• [11] Investigation of differential HDAC4 methylation patterns in eating disorders.Psychiatr Genet. 2018 Feb;28(1):12-15. doi: 10.1097/YPG.0000000000000189.
• [12] Neuroimaging and 5-HT2C receptor polymorphism: a HMPAO-SPECT study in healthy male probands using mCPP-challenge of the 5-HT2C receptor.Pharmacopsychiatry. 2004 Nov;37(6):286-91. doi: 10.1055/s-2004-832685.
• [13] Integrative analysis of shared genetic pathogenesis by obsessivecompulsive and eating disorders.Mol Med Rep. 2019 Mar;19(3):1761-1766. doi: 10.3892/mmr.2018.9772. Epub 2018 Dec 17.
• [14] A genome-wide association study of bipolar disorder with comorbid eating disorder replicates the SOX2-OT region.J Affect Disord. 2016 Jan 1;189:141-9. doi: 10.1016/j.jad.2015.09.029. Epub 2015 Sep 25.
• [15] Association of ghrelin receptor gene polymorphism with bulimia nervosa in a Japanese population.J Neural Transm (Vienna). 2006 Sep;113(9):1279-85. doi: 10.1007/s00702-005-0393-2. Epub 2005 Dec 16.
• [16] Role of the neurotrophin network in eating disorders' subphenotypes: body mass index and age at onset of the disease.J Psychiatr Res. 2010 Oct;44(13):834-40. doi: 10.1016/j.jpsychires.2010.01.009. Epub 2010 Mar 9.
• [17] Eating Disorders in Athletes: From Risk Management to Therapy.Endocr Metab Immune Disord Drug Targets. 2020;20(1):2-14. doi: 10.2174/1871530319666190418121446.
• [18] A receptor subtype involved in neuropeptide-Y-induced food intake.Nature. 1996 Jul 11;382(6587):168-71. doi: 10.1038/382168a0.
• [19] Modulation of feeding by chronic rAAV expression of a relaxin-3 peptide agonist in rat hypothalamus.Gene Ther. 2013 Jul;20(7):703-16. doi: 10.1038/gt.2012.83. Epub 2012 Nov 8.
• [20] Hypothalamic CRF1 receptor mechanisms are not sufficient to account for binge-like palatable food consumption in female rats.Int J Eat Disord. 2017 Oct;50(10):1194-1204. doi: 10.1002/eat.22767. Epub 2017 Aug 18.
• [21] Effect of dopamine receptor D4 (DRD4) haplotypes on general psychopathology in patients with eating disorders.Gene. 2018 May 15;654:43-48. doi: 10.1016/j.gene.2018.02.035. Epub 2018 Feb 15.
• [22] Variations in the preproghrelin gene correlate with higher body mass index, fat mass, and body dissatisfaction in young Japanese women.Am J Clin Nutr. 2007 Jul;86(1):25-32. doi: 10.1093/ajcn/86.1.25.
• [23] Association study in eating disorders: TPH2 associates with anorexia nervosa and self-induced vomiting.Genes Brain Behav. 2011 Mar;10(2):236-43. doi: 10.1111/j.1601-183X.2010.00660.x. Epub 2010 Nov 22.
• [24] Ghrelin gene variants and eating disorders.Vitam Horm. 2013;92:107-23. doi: 10.1016/B978-0-12-410473-0.00004-0.
• [25] Gender-based differential item functioning in measures of eating pathology.Int J Eat Disord. 2019 Sep;52(9):1047-1051. doi: 10.1002/eat.23126. Epub 2019 Jun 24.
• [26] Candidate genes for anorexia nervosa in the 1p33-36 linkage region: serotonin 1D and delta opioid receptor loci exhibit significant association to anorexia nervosa.Mol Psychiatry. 2003 Apr;8(4):397-406. doi: 10.1038/sj.mp.4001318.
• [27] Genetic variation at the TPH2 gene influences impulsivity in addition to eating disorders.Behav Genet. 2013 Jan;43(1):24-33. doi: 10.1007/s10519-012-9569-3. Epub 2012 Dec 14.
• [28] Behavioral effects of urotensin-II centrally administered in mice.Psychopharmacology (Berl). 2005 Nov;183(1):103-17. doi: 10.1007/s00213-005-0140-2. Epub 2005 Oct 22.
• [29] Kindness begins with yourself: The role of self-compassion in adolescent body satisfaction and eating pathology.Int J Eat Disord. 2019 Jul;52(7):809-816. doi: 10.1002/eat.23081. Epub 2019 Apr 12.
• [30] Evidence for ERP biomarkers of eating disorder symptoms in women.Biol Psychol. 2017 Feb;123:205-219. doi: 10.1016/j.biopsycho.2016.12.016. Epub 2017 Jan 3.
• [31] The CART (cocaine- and amphetamine-regulated transcript) system in appetite and drug addiction.J Pharmacol Exp Ther. 2007 Feb;320(2):499-506. doi: 10.1124/jpet.105.091512. Epub 2006 Jul 13.
• [32] Therapists' self-reported drift from dialectical behavior therapy techniques for eating disorders.Eat Behav. 2018 Jan;28:20-24. doi: 10.1016/j.eatbeh.2017.12.001. Epub 2017 Dec 12.
• [33] Self-report measures of loss of control over eating: Psychometric properties in clinical and non-clinical samples.Int J Eat Disord. 2018 Nov;51(11):1252-1260. doi: 10.1002/eat.22957. Epub 2018 Sep 28.
• [34] In vitro and in vivo characterization of the novel GABAB receptor positive allosteric modulator, 2-{1-[2-(4-chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]-2-piperidinyl}ethanol (CMPPE).Neuropharmacology. 2011 Oct-Nov;61(5-6):957-66. doi: 10.1016/j.neuropharm.2011.06.024. Epub 2011 Jul 5.
• [35] Food addiction among Spanish-speaking Latino/as residing in the United States.Eat Behav. 2018 Aug;30:61-65. doi: 10.1016/j.eatbeh.2018.05.009. Epub 2018 May 24.
• [36] Impact of NEGR1 genetic variability on psychological traits of patients with eating disorders.Pharmacogenomics J. 2015 Jun;15(3):278-83. doi: 10.1038/tpj.2014.53. Epub 2014 Sep 23.
• [37] Quantitative Mass Spectrometry Reveals Food Intake-Induced Neuropeptide Level Changes in Rat Brain: Functional Assessment of Selected Neuropeptides as Feeding Regulators.Mol Cell Proteomics. 2017 Nov;16(11):1922-1937. doi: 10.1074/mcp.RA117.000057. Epub 2017 Sep 1.
• [38] Genetic variants associated with disordered eating.Int J Eat Disord. 2013 Sep;46(6):594-608. doi: 10.1002/eat.22133. Epub 2013 Apr 9.
• [39] Comparison of associated features and drug treatment between co-occurring unipolar and bipolar disorders in depressed eating disorder patients.BMC Psychiatry. 2017 Feb 27;17(1):81. doi: 10.1186/s12888-017-1243-0.
• [40] The Italian Version of the Inventory of Interpersonal Problems (IIP-32): Psychometric Properties and Factor Structure in Clinical and Non-clinical Groups.Front Psychol. 2018 Mar 19;9:341. doi: 10.3389/fpsyg.2018.00341. eCollection 2018.
• [41] Anorexia nervosa is associated with Neuronatin variants.Psychiatr Genet. 2019 Aug;29(4):103-110. doi: 10.1097/YPG.0000000000000224.
• [42] Longitudinal study on novel neuropeptides phoenixin, spexin and kisspeptin in adolescent inpatients with anorexia nervosa - association with psychiatric symptoms.Nutr Neurosci. 2021 Nov;24(11):896-906. doi: 10.1080/1028415X.2019.1692494. Epub 2019 Nov 18.